5-Amino 1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule NNMT inhibitor studied primarily in metabolic, obesity, and NAD⁺ biology research. It is not a peptide and not an approved drug, but a preclinical research tool compound used to probe how cellular metabolism is regulated through nicotinamide and methylation pathways.

1. Chemical and Structural Profile

Core identity

• Chemical class: Quinolinium-based small molecule

• Molecular formula: C₁₀H₁₁N₂⁺ (free cation)

• Typical salt forms: iodide or chloride

• Molecular weight: ~159 g/mol (free base), ~286 g/mol (iodide salt)

• Structure type: Aromatic heterocycle with:

• N-methyl quinolinium (permanent positive charge)

• 5-position amino substitution

Structural significance

The molecule’s positive charge + aromatic ring system allows it to:

• Mimic NNMT substrates (nicotinamide/1-MNA transition state behavior)

• Bind competitively to the enzyme active site

• Penetrate cells despite being charged (unusual but important feature)

2. Biological Target and Core Mechanism

Primary target

• Enzyme: Nicotinamide N-methyltransferase (NNMT)

NNMT normally:

• Uses SAM (methyl donor)

• Converts nicotinamide → 1-methylnicotinamide

• Removes nicotinamide from the NAD⁺ salvage pathway

What 5-Amino 1MQ does

It inhibits NNMT, causing:

（1） Preservation of nicotinamide

• More substrate available for NAD⁺ production

（2） Reduced methyl-group consumption

• Less depletion of SAM (S-adenosylmethionine)

（3） Increased NAD⁺ availability (indirect)

• Supports mitochondrial energy pathways

（4）Metabolic reprogramming in fat tissue

• Shifts adipocytes away from storage toward energy use

3. Pharmacology and Bioactivity

Enzyme potency

Reported IC₅₀ ~1 µM range (selective NNMT inhibition)

Selectivity

Minimal inhibition of:

• Other methyltransferases

• Core NAD⁺ salvage enzymes

Bioavailability (animal data)

Oral administration in rats shows:

• ~38% oral bioavailability

• Reasonable systemic absorption

4. Mechanistic Effects in Biological Systems

A. Metabolic reprogramming (core effect)

Observed in preclinical models:

• ↓ Fat accumulation

• ↓ Adipocyte size

• ↑ Lipid oxidation

• ↑ Energy expenditure

This is often described as:

shifting fat cells from “storage mode” → “burn mode”

B. NAD⁺ metabolism effects

Because NNMT consumes nicotinamide:

Blocking it leads to:

• Increased NAD⁺ precursor availability

• Improved mitochondrial redox capacity

• Enhanced NAD⁺-dependent signaling (e.g., sirtuins)

C. Mitochondrial function

Reported downstream effects:

• ↑ ATP production efficiency

• ↑ Fatty acid oxidation

• ↑ metabolic flexibility

D. Insulin and glucose metabolism

Preclinical findings suggest:

• Improved insulin sensitivity

• Better glucose uptake in peripheral tissues

• Reduced metabolic stress in adipose tissue

5. Preclinical Efficacy Summary

Strongest evidence (animal studies)

Body composition

• Significant fat mass reduction

• Reduced adipose tissue inflammation

• No strong appetite suppression effect

Metabolic function

• Increased resting energy expenditure

• Improved insulin signaling markers

Tissue-specific effects

• Most pronounced in adipose tissue and liver metabolism models

6. Safety and Toxicology Profile (Known Limits)

Human data

• ❌ No completed human clinical trials

• ❌ No established therapeutic dosing

Animal data

• Generally well tolerated in short-term studies

• Long-term toxicity not well characterized

Theoretical concerns

Because it affects methylation metabolism:

• Possible SAM depletion imbalance (theoretical)

• Potential epigenetic or methylation pathway shifts

• Unknown long-term endocrine or hepatic effects

7. Pharmacokinetics (what is known)

From rodent and analytical studies:

• Absorbed orally (moderate bioavailability)

• Detectable plasma levels after oral dosing

• Measured via LC-MS/MS methods in plasma and urine

8. Research Applications

5-Amino 1MQ is mainly used to study:

（1） Obesity biology

• Why NNMT is upregulated in obese adipose tissue

（2）NAD⁺ metabolism

• How nicotinamide is partitioned between pathways

（3）Methylation balance

• SAM consumption vs NAD⁺ production trade-offs

（4）Metabolic disease modeling

• Insulin resistance

• Fatty liver disease

• Energy imbalance disorders

（5）Aging and mitochondrial research

• NAD⁺ decline with age

• Sirtuin activation pathways (indirectly)

9. Limitations of Current Science

Despite strong preclinical interest:

• No large human trials exist

• No FDA-approved medical use

• No standardized dosing or clinical protocol

• Effects may differ significantly in humans vs rodents

10. Overall Scientific Conclusion

5-Amino 1MQ is best understood as:

A selective NNMT inhibitor tool compound that alters NAD⁺ metabolism and fat-cell energetics in preclinical models.

What is well supported:

• NNMT inhibition is real and measurable

• Fat metabolism changes occur in animals

• NAD⁺ pathway modulation is biologically plausible

What is NOT established:

• Human fat-loss efficacy

• Long-term safety

• Clinical therapeutic value

Bottom Line

5-Amino 1MQ is a mechanistically interesting metabolic research compound that:

• Targets NNMT

• Influences NAD⁺ biology

• Produces fat-loss and metabolic effects in animals

But it remains:

Experimental, preclinical, and not validated as a human therapy

If you want, I can next compare it directly with GLP-1 drugs (semaglutide, tirzepatide) or explain how it stacks conceptually with NAD⁺ boosters like NMN/NR—that’s where the differences become much clearer.